
10 Literaturverzeichnis

1. **Cady B, Rossi R** 1988 An expanded view of risk-group definition in differentiated thyroid carcinoma. *Surgery* 104:947-53.
2. **Hay ID, Bergstralh EJ, Goellner JR, et al.** 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. *Surgery* 114:1050-7; discussion 1057-8.
3. **Hedinger C** 1988 Histological typing of thyroid tumours. WHO International Histological Classification of Tumours., 2nd ed. ed. Springer, Berlin Heidelberg New York
4. **Pfannenstiel P, Hotze L, Saller B** 1999 Schilddr senkrankheiten. Diagnose und Therapie. Berliner Med. Verl.-Anst., Berlin
5. **van de Graaf SA, Ris-Stalpers C, Pauws E, et al.** 2001 Up to date with human thyroglobulin. *J Endocrinol* 170:307-21.
6. **Kohn LD, Suzuki K, Nakazato M, Royaux I, et al.** 2001 Effects of thyroglobulin and pendrin on iodide flux through the thyrocyte. *Trends Endocrinol Metab* 12:10-6.
7. **Pauws E, Veenboer GJ, Smit JW, et al** 2004 Genes differentially expressed in thyroid carcinoma identified by comparison of SAGE expression profiles. *Faseb J* 18:560-1
8. **Kim PS, Arvan P** 1995 Calnexin and BiP act as sequential molecular chaperones during thyroglobulin folding in the endoplasmic reticulum. *J Cell Biol* 128:29-38.
9. **Kim PS, Arvan P** 1998 Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. *Endocr Rev* 19:173-202.
10. **Arvan P, Kim PS, Kuliawat R, et al.** 1997 Intracellular protein transport to the thyrocyte plasma membrane: potential implications for thyroid physiology. *Thyroid* 7:89-105.
11. **Williams E** 1985 Dietary iodine and thyroid cancer. In: Hall R, K berling J (eds) *Thyroid disorders associated with iodine deficiency and excess*. Raven, New York; p 201
12. **Smanik PA, Liu Q, Furminger TL, et al.** 1996 Cloning of the human sodium iodide symporter. *Biochem Biophys Res Commun* 226:339-45.
13. **Royaux IE, Wall SM, Karniski LP, et al.** 2001 Pendrin, encoded by the Pendred syndrome gene, resides in the apical region of renal intercalated cells and mediates bicarbonate secretion. *Proc Natl Acad Sci U S A* 98:4221-6.
14. **Lacroix L, Nocera M, Mian C, et al.** 2001 Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. *Thyroid* 11:1017-23
15. **Deshpande V, Venkatesh SG** 1999 Thyroglobulin, the prothyroid hormone: chemistry, synthesis and degradation. *Biochim Biophys Acta* 1430:157-78.
16. **Dunn JT, Dunn AD** 2001 Update on intrathyroidal iodine metabolism. *Thyroid* 11:407-14.
17. **Taurog A** 1996 Hormone Synthesis: Thyroid iodine metabolism. In: Braverman L, Utiger R (eds) *The Thyroid: A Fundamental and Clinical Text.*, 3rd ed. Lippincott-Raven, Philadelphia; pp 47-81

18. **Dunn J** 1996 Thyroglobulin: Chemistry and biosynthesis. In: Braverman L, Utiger R (eds) *The Thyroid: A Fundamental and Clinical Text.*, 3rd ed. Lippincott-Raven, Philadelphia; pp 85-95
19. **Berndorfer U, Wilms H, Herzog V** 1996 Multimerization of thyroglobulin (TG) during extracellular storage: isolation of highly cross-linked TG from human thyroids. *J Clin Endocrinol Metab* 81:1918-26.
20. **Dunn J** 1996 Thyroglobulin retrieval and the endocytic pathway. In: Braverman L, Utiger R (eds) *The Thyroid. A Fundamental and Clinical Text.* Lippincott-Raven, Philadelphia; pp 81-84
21. **Bastiani P, Papandreou MJ, Blanck O, et al.** 1995 On the relationship between completion of N-acetyllactosamine oligosaccharide units and iodine content of thyroglobulin: a reinvestigation. *Endocrinology* 136:4204-9.
22. **Brix K, Linke M, Tepel C, Herzog V** 2001 Cysteine proteinases mediate extracellular prohormone processing in the thyroid. *Biol Chem* 382:717-25.
23. **Hayden LJ, Shagrin JM, Young JA** 1970 Micropuncture investigation of the anion content of colloid from single rat thyroid follicles. A micromethod for the simultaneous determination of iodide and chloride in nanomole quantities. *Pflugers Arch* 321:173-86.
24. **Lisi S, Pinchera A, McCluskey RT, et al.** 2003 Preferential megalin-mediated transcytosis of low-hormonogenic thyroglobulin: a control mechanism for thyroid hormone release. *Proc Natl Acad Sci U S A* 100:14858-63.
25. **Saber-Lichtenberg Y, Brix K, Schmitz A, et al.** 2000 Covalent cross-linking of secreted bovine thyroglobulin by transglutaminase. *Faseb J* 14:1005-14.
26. **Brix K, Summa W, Lottspeich F, Herzog V** 1998 Extracellularly occurring histone H1 mediates the binding of thyroglobulin to the cell surface of mouse macrophages. *J Clin Invest* 102:283-93.
27. **Trowbridge IS, Collawn JF, Hopkins CR** 1993 Signal-dependent membrane protein trafficking in the endocytic pathway. *Annu Rev Cell Biol* 9:129-61.
28. **Marino M, McCluskey RT** 2000 Role of thyroglobulin endocytic pathways in the control of thyroid hormone release. *Am J Physiol Cell Physiol* 279:C1295-306.
29. **van den Hove MF, Couvreur M, de Visscher M, Salvatore G** 1982 A new mechanism for the reabsorption of thyroid iodoproteins: selective fluid pinocytosis. *Eur J Biochem* 122:415-22.
30. **Zheng G, Marino M, Zhao J, McCluskey RT** 1998 Megalin (gp330): a putative endocytic receptor for thyroglobulin (Tg). *Endocrinology* 139:1462-5.
31. **Ulianich L, Suzuki K, Mori A, et al.** 1999 Follicular thyroglobulin (TG) suppression of thyroid-restricted genes involves the apical membrane asialoglycoprotein receptor and TG phosphorylation. *J Biol Chem* 274:25099-107.
32. **Suzuki K, Nakazato M, Ulianich L, et al.** 2000 Thyroglobulin autoregulation of thyroid-specific gene expression and follicular function. *Rev Endocr Metab Disord* 1:217-24.
33. **Marino M, Chiovato L, Mitsiades N, et al.** 2000 Circulating thyroglobulin transcytosed by thyroid cells in complexed with secretory components of its endocytic receptor megalin. *J Clin Endocrinol Metab* 85:3458-67.
34. **Pacifico F, Montuori N, Mellone S, et al.** 2003 The RHL-1 subunit of the asialoglycoprotein receptor of thyroid cells: cellular localization and its role in thyroglobulin endocytosis. *Mol Cell Endocrinol* 208:51-9
35. **Marino M, Pinchera A, McCluskey RT, Chiovato L** 2001 Megalin in thyroid physiology and pathology. *Thyroid* 11:47-56.

36. **Christensen EI, Birn H** 2002 Megalin and cubilin: multifunctional endocytic receptors. *Nat Rev Mol Cell Biol* 3:256-66.
37. **Spencer CA** 2000 Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. *Endocr Pract* 6:481-4.
38. **Blanck O, Perrin C, Mziaut H, et al.** 1995 Molecular cloning, cDNA analysis, and localization of a monomer of the N-acetylglucosamine-specific receptor of the thyroid, NAGR1, to chromosome 19p13.3-13.2. *Genomics* 27:561
39. **Marino M, Lisi S, Pinchera A, et al.** 2001 Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. *Thyroid* 11:177-85.
40. **Marino M, Chiovato L, Lisi S, et al.** 2001 Binding of the low density lipoprotein receptor-associated protein (RAP) to thyroglobulin (Tg): putative role of RAP in the Tg secretory pathway. *Mol Endocrinol* 15:1829-37.
41. **de Vijlder JJ, Ris-Stalpers C, Vulsma T** 1999 On the origin of circulating thyroglobulin. *Eur J Endocrinol* 140:7-8.
42. **Lezoualc'h F, Hassan AH, Giraud P, et al.** 1992 Assignment of the beta-thyroid hormone receptor to 3,5,3'-triiodothyronine-dependent inhibition of transcription from the thyrotropin-releasing hormone promoter in chick hypothalamic neurons. *Mol Endocrinol* 6:1797-804.
43. **Chin WW, Carr FE, Burnside J, Darling DS** 1993 Thyroid hormone regulation of thyrotropin gene expression. *Recent Prog Horm Res* 48:393-414.
44. **Wolff J, Jones AB** 1971 The purification of bovine thyroid plasma membranes and the properties of membrane-bound adenyl cyclase. *J Biol Chem* 246:3939-47.
45. **Laurent E, Mockel J, Van Sande J, Graff I, Dumont JE** 1987 Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. *Mol Cell Endocrinol* 52:273-8.
46. **Philp NJ, Grollman EF** 1986 Thyrotropin and norepinephrine stimulate the metabolism of phosphoinositides in FRTL-5 thyroid cells. *FEBS Lett* 202:193-6.
47. **Dumont JE, Lamy F, Roger P, Maenhaut C** 1992 Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. *Physiol Rev* 72:667-97.
48. **Milazzo G, La Rosa GL, Catalfamo R, Vigneri R, Belfiore A** 1992 Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. *J Cell Biochem* 49:231-8.
49. **Scanlon M, Toft A** 1996 Regulation of thyrotropin secretion. In: Braverman L, Utiger R (eds) *The Thyroid: A Fundamental and Clinical Text*. Lippincott-Raven, Philadelphia; pp 220-240
50. **Robbins J** 1996 Thyroid hormone transport proteins and the physiology of hormone binding. In: Braverman L, Utiger R (eds) *The Thyroid. A Fundamental and Clinical Text*. Lippincott-Raven, Philadelphia; pp 96-110
51. **Friesema EC, Jansen J, Milici C, Visser TJ** 2005 Thyroid hormone transporters. *Vitam Horm* 70:137-67
52. **Davis PJ, Tillmann HC, Davis FB, Wehling M** 2002 Comparison of the mechanisms of nongenomic actions of thyroid hormone and steroid hormones. *J Endocrinol Invest* 25:377-88.
53. **Bernal J, Guadano-Ferraz A** 2002 Analysis of thyroid hormone-dependent genes in the brain by in situ hybridization. *Methods Mol Biol* 202:71-90.
54. **Smith JW, Evans AT, Costall B, Smythe JW** 2002 Thyroid hormones, brain function and cognition: a brief review. *Neurosci Biobehav Rev* 26:45-60.

55. **Oppenheimer JH, Schwartz HL** 1997 Molecular basis of thyroid hormone-dependent brain development. *Endocr Rev* 18:462-75.
56. **Bätge B, Renz-Polster H** 2000 Schilddrüse. In: Braun J, Renz-Polster H (eds) *Basislehrbuch Innere Medizin*. Urban & Fischer Verlag, München; pp 702-718
57. **Klett M** 1997 Epidemiology of congenital hypothyroidism. *Exp Clin Endocrinol Diabetes* 105:19-23.
58. **Macchia PE, Felice MD, Lauro RD** 1999 Molecular genetics of congenital hypothyroidism. *Curr Opin Genet Dev* 9:289-94.
59. **De Felice M, Ovitt C, Biffali E, et al.** 1998 A mouse model for hereditary thyroid dysgenesis and cleft palate. *Nat Genet* 19:395-8.
60. **Kimura S, Hara Y, Pineau T, et al.** 1996 The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. *Genes Dev* 10:60-9.
61. **Damante G, Di Lauro R** 1994 Thyroid-specific gene expression. *Biochim Biophys Acta* 1218:255-66.
62. **Iwatani N, Mabe H, Devriendt K, et al.** 2000 Deletion of NKX2.1 gene encoding thyroid transcription factor-1 in two siblings with hypothyroidism and respiratory failure. *J Pediatr* 137:272-6.
63. **Lapi P, Macchia PE, Chiovato L, et al.** 1997 Mutations in the gene encoding thyroid transcription factor-1 (TTF-1) are not a frequent cause of congenital hypothyroidism (CH) with thyroid dysgenesis. *Thyroid* 7:383-7.
64. **Perna MG, Civitareale D, De Filippis V, et al.** 1997 Absence of mutations in the gene encoding thyroid transcription factor-1 (TTF-1) in patients with thyroid dysgenesis. *Thyroid* 7:377-81.
65. **Pohlenz J, Dumitrescu A, Zundel D, et al.** 2002 Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice. *J Clin Invest* 109:469-73.
66. **Bamforth JS, Hughes IA, Lazarus JH, Weaver CM, Harper PS** 1989 Congenital hypothyroidism, spiky hair, and cleft palate. *J Med Genet* 26:49-51.
67. **Clifton-Bligh RJ, Wentworth JM, Heinz P, et al.** 1998 Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. *Nat Genet* 19:399-401.
68. **Zannini M, Avantaggiato V, Biffali E, et al.** 1997 TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. *Embo J* 16:3185-97.
69. **Riede U, Saeger W, Klöppel G, Oberholzer M** 1995 *Endokrines System. Schilddrüse*. In: Riede U, Schaefer H (eds) *Allgemeine und spezielle Pathologie*. Thieme, Stuttgart, New York; pp 999-1001
70. **Congdon T, Nguyen LQ, Nogueira CR, et al.** 2001 A novel mutation (Q40P) in PAX8 associated with congenital hypothyroidism and thyroid hypoplasia: evidence for phenotypic variability in mother and child. *J Clin Endocrinol Metab* 86:3962-7.
71. **Macchia PE** 2000 Recent advances in understanding the molecular basis of primary congenital hypothyroidism. *Mol Med Today* 6:36-42.
72. **Macchia PE, Lapi P, Krude H, et al.** 1998 PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. *Nat Genet* 19:83-6.
73. **Kopp P** 2002 Perspective: genetic defects in the etiology of congenital hypothyroidism. *Endocrinology* 143:2019-24.
74. **Nutt SL, Vambrie S, Steinlein P, et al.** 1999 Independent regulation of the two Pax5 alleles during B-cell development. *Nat Genet* 21:390-5.

75. **Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S** 1995 Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. *N Engl J Med* 332:155-60.
76. **Biebermann H, Schoneberg T, Krude H, et al.** 1997 Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. *J Clin Endocrinol Metab* 82:3471-80.
77. **Gagne N, Parma J, Deal C, Vassart G, Van Vliet G** 1998 Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities? *J Clin Endocrinol Metab* 83:1771-5.
78. **Weinstein LS, Yu S, Warner DR, Liu J** 2001 Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. *Endocr Rev* 22:675-705.
79. **Schmitz-Moormann P, Gebert G, Thomas C** 1994 *Allgemeine Pathologie*, 4. erw. Auflage ed. Schattauer Verlagsgesellschaft mbH, Stuttgart
80. **Hampel R, Kulberg T, Klein K, et al.** 1995 [Goiter incidence in Germany is greater than previously suspected]. *Med Klin* 90:324-9.
81. **Riede U, Saeger W, Klöppel G, Oberholzer M** 1995 *Endokrines System. Schilddrüse*. In: Riede U, Schaefer H (eds) *Allgemeine und spezielle Pathologie*. Thieme, Stuttgart, New York; pp 992-1004
82. **Gimm O** 2001 Thyroid cancer. *Cancer Lett* 163:143-56.
83. **Fleming ID, Phillips JL, Menck HR, et al.** 1997 The National Cancer Data Base report on recent hospital cancer program progress toward complete American Joint Committee on Cancer/TNM staging. *Cancer* 80:2305-10.
84. **Scheumann GF, Gimm O, Wegener G, et al.** 1994 Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. *World J Surg* 18:559-67; discussion 567-8.
85. **Tsang RW, Brierley JD, Simpson WJ, et al.** 1998 The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. *Cancer* 82:375-88.
86. **Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA** 1988 Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. *J Clin Endocrinol Metab* 67:501-8.
87. **Shaha AR, Loree TR, Shah JP** 1995 Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. *Surgery* 118:1131-6; discussion 1136-8.
88. **Mazzaferri EL, Massoli N** 2002 Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. *Endocr Relat Cancer* 9:227-47.
89. **Schmitt-Gräf A** 1998 *Schilddrüsenneoplasien- Pathologische Klassifikation*. In: Buhr H, Mann B (eds) *Operationskurs Schilddrüse. Pathophysiologie und operative Technik*. Blackwell-Wissenschafts- Verlag, Berlin, Wien; pp 21-25
90. **Hamilton TE, van Belle G, LoGerfo JP** 1987 Thyroid neoplasia in Marshall Islanders exposed to nuclear fallout. *Jama* 258:629-35.
91. **Shibata Y, Yamashita S, Masyakin VB, et al.** 2001 15 years after Chernobyl: new evidence of thyroid cancer. *Lancet* 358:1965-6.
92. **Malchoff CD, Malchoff DM** 2002 The genetics of hereditary nonmedullary thyroid carcinoma. *J Clin Endocrinol Metab* 87:2455-9.
93. **Matakidou A, Hamel N, Popat S, et al.** 2004 Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. *Carcinogenesis* 25:369-73

94. **Kim DS, McCabe CJ, Buchanan MA, Watkinson JC** 2003 Oncogenes in thyroid cancer. *Clin Otolaryngol* 28:386-95.
95. **Wynford-Thomas D** 1997 Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. *Horm Res* 47:145-57.
96. **Sarlis NJ** 2000 Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects. *Rev Endocr Metab Disord* 1:183-96.
97. **Segev DL, Umbricht C, Zeiger MA** 2003 Molecular pathogenesis of thyroid cancer. *Surg Oncol* 12:69-90.
98. **Tallini G, Benvenga S, Robbins J, et al.** 2002 Molecular pathobiology of thyroid neoplasms. *Endocr Pathol* 13:271-88.
99. **N.N.** 2001 AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. *Endocr Pract* 7:202-20.
100. **Ringel MD, Ladenson PW** 2004 Controversies in the follow-up and management of well-differentiated thyroid cancer. *Endocr Relat Cancer* 11:97-116
101. **Haugen BR, Pacini F, Reiners C, et al.** 1999 A Comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. *J Clin Endocrinol Metab* 84:3877- 3885
102. www.deutschkrebsgesellschaft.de/ISTO
103. **Maruyama M, Kato R, Kobayashi S, Kasuga Y** 1998 A method to differentiate between thyroglobulin derived from normal thyroid tissue and from thyroid carcinoma based on analysis of reactivity to lectins. *Arch Pathol Lab Med* 122:715-20.
104. **Pacini F, Lippi F** 1999 Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): Serum thyroglobulin measurement. *J Endocrinol Invest* 22:25-29
105. **de Geus-Oei LF, Oei HY, Hennemann G, et al.** 2002 Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 29:768-74.
106. **Luster M, Lassmann M, Haenscheid H, et al.** 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 85:3640-5.
107. **Mazzaferri EL, Kloos RT** 2000 Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. *Thyroid* 10:767-78.
108. **Reiners C, LM, Laßmann M.** 1999 Clinical experience with recombinant human thyroid -stimulating hormone (rhTSH): Whole- body scanning with iodine- 131. *J Endocrinol Invest* 22:17-24
109. **Tubiana M, Schlumberger M, Rougier P, et al.** 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. *Cancer* 55:794-804.
110. www.medknowledge.de
111. **Petrides P** 2003 Tumorgewebe. Springer Verlag., Berlin, Heidelberg, New York.
112. **Torrens JI, Burch HB** 2001 Serum thyroglobulin measurement. Utility in clinical practice. *Endocrinol Metab Clin North Am* 30:429-67.
113. **Mazzaferri EL, Robbins RJ, Spencer CA, et al.** 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. *J Clin Endocrinol Metab* 88:1433-41.
114. **Mullis KB** 1990 Target amplification for DNA analysis by the polymerase chain reaction. *Ann Biol Clin (Paris)* 48:579-82

115. **Haber RS** 1998 The diagnosis of recurrent thyroid cancer--a new approach. *J Clin Endocrinol Metab* 83:4189-90
116. **Ghossein RA, Bhattacharya S** 2000 Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. *Eur J Cancer* 36:1681-94
117. **Smith B, Selby P, Southgate J, et al.** 1991 Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. *Lancet* 338:1227-9
118. **Mason ME, Dunn AD, Wortsman J, et al.** 1995 Thyroids from siblings with Pendred's syndrome contain thyroglobulin messenger ribonucleic acid variants. *J Clin Endocrinol Metab* 80:497-503.
119. **Ditkoff BA, Marvin MR, Yemul S, et al.** 1996 Detection of circulating thyroid cells in peripheral blood. *Surgery* 120:959-64; discussion 964-5.
120. **Goretzki PE, Simon D, Frilling A, et al.** 1993 Surgical reintervention for differentiated thyroid cancer. *Br J Surg* 80:1009-12.
121. **Schmutzler C, Schmitt TL, Glaser F, Loos U, Kohrle J** 2002 The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. *Mol Cell Endocrinol* 189:145-55
122. **Chomczynski P, Sacchi N** 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156-9
123. **Takano T, Miyauchi A, Matsuzuka F, et al.** 2000 Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas. *J Clin Endocrinol Metab* 85:765-8.
124. **Tallini G, Ghossein RA, Emanuel J, et al.** 1998 Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. *J Clin Oncol* 16:1158-66.
125. **Lee LG, Connell CR, Bloch W** 1993 Allelic discrimination by nick-translation PCR with fluorogenic probes. *Nucleic Acids Res* 21:3761-6
126. www.ncbi.nlm.gov
127. **Chelly J, Concordet JP, Kaplan JC, Kahn A** 1989 Illegitimate transcription: transcription of any gene in any cell type. *Proc Natl Acad Sci U S A* 86:2617-21.
128. **Sarkar G, Sommer SS** 1989 Access to a messenger RNA sequence or its protein product is not limited by tissue or species specificity. *Science* 244:331-4.
129. **Ringel MD** 2004 Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays. *J Clin Endocrinol Metab* 89:29-32
130. **Sherman SI** 2003 Thyroid carcinoma. *Lancet* 361:501-11
131. **Schlumberger M, Berg G, Cohen O, et al.** 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. *Eur J Endocrinol* 150:105-12
132. **Bockmann B, Grill HJ, Giesing M** 2001 Molecular characterization of minimal residual cancer cells in patients with solid tumors. *Biomol Eng* 17:95-111.
133. **Anker P, Stroun M** 2000 Circulating DNA in plasma or serum. *Medicina (B Aires)* 60:699-702.
134. **Ng EK, Tsui NB, Lam NY, et al.** 2002 Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. *Clin Chem* 48:1212-7
135. **Tsui NB, Ng EK, Lo YM** 2002 Stability of endogenous and added RNA in blood specimens, serum, and plasma. *Clin Chem* 48:1647-53

136. **Eszlinger M, Neumann S, Otto L, Paschke R** 2002 Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. *Eur J Endocrinol* 147:575-82.
137. **Dickover RE, Herman SA, Saddiq K, et al.** 1998 Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. *J Clin Microbiol* 36:1070-3
138. **Holodny M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC** 1991 Inhibition of human immunodeficiency virus gene amplification by heparin. *J Clin Microbiol* 29:676-9
139. **Elisei R, Vivaldi A, Agate L, et al.** 2004 Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. *J Clin Endocrinol Metab* 89:33-9.
140. **Span PN, Slegers MJ, Van Den Broek WJ, et al.** 2003 Quantitative detection of peripheral thyroglobulin mRNA has limited clinical value in the follow-up of thyroid cancer patients. *Ann Clin Biochem* 40:94-9.
141. **Zippelius A, Pantel K** 2000 RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. *Ann N Y Acad Sci* 906:110-23.
142. **El-Hefnawy T, Raja S, Kelly L, et al.** 2004 Characterization of Amplifiable, Circulating RNA in Plasma and Its Potential as a Tool for Cancer Diagnostics. *Clin Chem* 12:12
143. **McFaul SJ, Bowman PD, Villa VM** 2000 Hemoglobin stimulates the release of proinflammatory cytokines from leukocytes in whole blood. *J Lab Clin Med* 135:263-9
144. **Zippelius A, Lutterbuse R, Riethmuller G, et al.** 2000 Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells. *Clin Cancer Res* 6:2741-50.
145. **Bustin SA** 2002 Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. *J Mol Endocrinol* 29:23-39
146. **Bustin SA, Nolan T** 2004 Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. *J Biomol Tech* 15:155-66
147. **Li D, Butt A, Clarke S, Swaminathana R** 2004 Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects. *Ann N Y Acad Sci* 1022:147-51.
148. **Malboeuf CM, Isaacs SJ, Tran NH, et al.** 2001 Thermal effects on reverse transcription: improvement of accuracy and processivity in cDNA synthesis. *Biotechniques* 30:1074-8, 1080, 1082, passim
149. **Gupta M, Taguba L, Arcaga R, et al.** 2002 Detection of Circulating Thyroid Cancer Cells by Reverse Transcription-PCR for Thyroid-stimulating Hormone Receptor and Thyroglobulin: the Importance of Primer Selection. *Clin Chem* 48:1862-1865
150. **Rubin E, Levy AA** 1996 A mathematical model and a computerized simulation of PCR using complex templates. *Nucleic Acids Res* 24:3538-45.
151. **Schamhart D, Swinnen J, Kurth KH, et al.** 2003 Numeric definition of the clinical performance of the nested reverse transcription-PCR for detection of hematogenous epithelial cells and correction for specific mRNA of non-target cell origin as evaluated for prostate cancer cells. *Clin Chem* 49:1458-66.

152. **Karrer EE, Lincoln JE, Hogenhout S, et al.** 1995 In situ isolation of mRNA from individual plant cells: creation of cell-specific cDNA libraries. *Proc Natl Acad Sci U S A* 92:3814-8.
153. **Thelwell N, Millington S, Solinas A, et al.** 2000 Mode of action and application of Scorpion primers to mutation detection. *Nucleic Acids Res* 28:3752-61
154. **Whitcombe D, Theaker J, Guy SP, Brown T, Little S** 1999 Detection of PCR products using self-probing amplicons and fluorescence. *Nat Biotechnol* 17:804-7
155. **Ringel MD, Ladenson PW, Levine MA** 1998 Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. *J Clin Endocrinol Metab* 83:4435-42.
156. **Wingo ST, Ringel MD, Anderson JS, et al.** 1999 Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. *Clin Chem* 45:785-9.
157. **Savagner F, Rodien P, Reynier P, et al.** 2002 Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients. *J Clin Endocrinol Metab* 87:635-9.
158. **Takano T, Miyauchi A, Yoshida H, et al.** 2001 Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy. *Br J Cancer* 85:102-6.
159. **Cooper DN, Berg LP, Kakkar VV, Reiss J** 1994 Ectopic (illegitimate) transcription: new possibilities for the analysis and diagnosis of human genetic disease. *Ann Med* 26:9-14.
160. **Kimoto Y** 1998 A single human cell expresses all messenger ribonucleic acids: the arrow of time in a cell. *Mol Gen Genet* 258:233-9.
161. **Spitzweg C, Joba W, Heufelder AE** 1999 Expression of thyroid-related genes in human thymus. *Thyroid* 9:133-41.
162. **Kyewski B, Derbinski J** 2004 Self-representation in the thymus: an extended view. *Nat Rev Immunol* 4:688-98.
163. **Sellitti DF, Akamizu T, Doi SQ, et al.** 2000 Renal expression of two 'thyroid-specific' genes: thyrotropin receptor and thyroglobulin. *Exp Nephrol* 8:235-43.
164. **Lau SK, Luthringer DJ, Eisen RN** 2002 Thyroid transcription factor-1: a review. *Appl Immunohistochem Mol Morphol* 10:97-102.
165. **Torban E, Goodyer P** 1998 What PAX genes do in the kidney. *Exp Nephrol* 6:7-11.
166. **Bugalho MJ, Domingues RS, Pinto AC, et al.** 2001 Detection of thyroglobulin mRNA transcripts in peripheral blood of individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. *Eur J Endocrinol* 145:409-13.
167. **Ladenson PW** 2000 Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. *Semin Nucl Med* 30:98-106.
168. **McDougall IR, Weigel RJ** 2001 Recombinant human thyrotropin in the management of thyroid cancer. *Curr Opin Oncol* 13:39-43.
169. **Ohta K, Endo T, Onaya T** 1991 The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues. *Biochem Biophys Res Commun* 174:1148-53
170. **Sheils OM, Sweeney EC** 1999 TSH receptor status of thyroid neoplasms--TaqMan RT-PCR analysis of archival material. *J Pathol* 188:87-92
171. **Gerard AC, Daumerie C, Mestdagh C, et al.** 2003 Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved

- in iodine metabolism in thyroid carcinomas. *Thyroid cancer. J Clin Endocrinol Metab* 88:4977-83.
172. **Maenhaut C, Brabant G, Vassart G, Dumont JE** 1992 In vitro and in vivo regulation of thyrotropin receptor mRNA levels in dog and human thyroid cells. *J Biol Chem* 267:3000-7
173. **Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM** 2000 Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. *Thyroid* 10:211-7.
174. **Lazar V, Bidart JM, Caillou B, et al.** 1999 Expression of the Na⁺/I⁻ symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. *J Clin Endocrinol Metab* 84:3228-34.
175. **Ghossein RA, Rosai J, Scher HI, et al.** 1997 Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. *Urology* 50:100-5.
176. **Feilchenfeldt J, Totsch M, Sheu SY, et al.** 2003 Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. *Mod Pathol* 16:1117-23.
177. **Ringel MD, Anderson J, Souza SL, et al.** 2001 Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. *Mod Pathol* 14:289-96.
178. **Robbins RJ, Srivastava S, Shaha A, et al.** 2004 Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. *J Clin Endocrinol Metab* 89:6010-6
179. **Johnson PW, Burchill SA, Selby PJ** 1995 The molecular detection of circulating tumour cells. *Br J Cancer* 72:268-76.
180. **Tanaka K, Otsuki T, Sonoo H, et al.** 2000 Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR. *Eur J Endocrinol* 142:340-6.
181. **Fenton C, Anderson JS, Patel AD, et al.** 2001 Thyroglobulin messenger ribonucleic acid levels in the peripheral blood of children with benign and malignant thyroid disease. *Pediatr Res* 49:429-34.
182. **Grammatopoulos D, Elliott Y, Smith SC, et al.** 2003 Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer. *Mol Pathol* 56:162-6.
183. **Baudin E, Do Cao C, Cailleux AF, et al.** 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. *J Clin Endocrinol Metab* 88:1107-11
184. **Bellantone R, Lombardi CP, Bossola M, et al.** 2001 Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. *Cancer* 92:2273-9.
185. **Biscolla RP, Cerutti JM, Maciel RM** 2000 Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood. *J Clin Endocrinol Metab* 85:3623-7.
186. **Bojunga J, Roddiger S, Stanisch M, et al.** 2000 Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. *Br J Cancer* 82:1650-5.
187. **Chinnappa P, Taguba L, Arciaga R, et al.** 2004 Detection of thyrotropin-receptor messenger ribonucleic Acid (mRNA) and thyroglobulin mRNA tran-

- scripts in peripheral blood of patients with thyroid disease. *J Clin Endocrinol Metab* 89:3705-9.
188. **Fugazzola L, Mihalich A, Persani L, et al.** 2002 Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission. *J Clin Endocrinol Metab* 87:3201-8.
 189. **Denizot A, Delfino C, Dutour-Meyer A, et al.** 2003 Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer. *Thyroid* 13:867-72.
 190. **Ringel MD, Balducci-Silano PL, Anderson JS, et al.** 1999 Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. *J Clin Endocrinol Metab* 84:4037-42.
 191. **Fenton CL, Patel A, Burch HB, et al.** 2001 Nuclear localization of thyroid transcription factor-1 correlates with serum thyrotropin activity and may be increased in differentiated thyroid carcinomas with aggressive clinical course. *Ann Clin Lab Sci* 31:245-52.
 192. **Barzon L, Boscaro M, Pacenti M, et al.** 2004 Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse. *Int J Cancer* 110:914-20.
 193. **Weiss L** 1990 Metastatic inefficiency. *Adv Cancer Res* 54:159-211
 194. **Cameron MD, Schmidt EE, Kerkvliet N, et al.** 2000 Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. *Cancer Res* 60:2541-6
 195. **Luzzi KJ, MacDonald IC, Schmidt EE, et al.** 1998 Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. *Am J Pathol* 153:865-73
 196. **Mertens IJ, De Klerk JM, Zelissen PM, et al.** 1999 Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer. *Clin Nucl Med* 24:346-9
 197. **Hocevar M, Auersperg M, Stanovnik L** 1997 The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. *Eur J Surg Oncol* 23:208-10
 198. **Westbury C, Vini L, Fisher C, Harmer C** 2000 Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. *Thyroid* 10:171-6.
 199. **Brendel AJ, Lambert B, Guyot M, et al.** 1990 Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. *Eur J Nucl Med* 16:35-8
 200. **Muller-Gartner HW, Schneider C** 1988 Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. *Cancer* 61:976-81
 201. **van Herle AJ, van Herle KA** 1997 Thyroglobulin in benign and malignant thyroid disease. In: Falk SA (ed) *Thyroid disease: Endocrinology, Surgery, Nuclear medicine and Radiotherapy*, 3rd ed. Lipincott-Raven, Washington; pp 587- 595
 202. **Qiu SD, Young CY, Bilhartz DL, et al.** 1990 In situ hybridization of prostate-specific antigen mRNA in human prostate. *J Urol* 144:1550-6
 203. **Tickoo SK, Pittas AG, Adler M, et al.** 2000 Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. *Arch Pathol Lab Med* 124:1440-7.

204. **Varghese BT, Mathews A, Pandey M, Pradeep V** 2003 Unusual metastasis of papillary thyroid carcinoma to larynx and hypopharynx a case report. *World J Surg Oncol* 1:7.
205. **Gerard AC, Deneff JF, Colin IM, Van Den Hove MF** 2004 Evidence for processing of compact insoluble thyroglobulin globules in relation with follicular cell functional activity in the human and the mouse thyroid. *Eur J Endocrinol* 150:73-80.
206. **Schlumberger M, Tubiana M, De Vathaire F, et al.** 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 63:960-7
207. **Schlumberger M, Baudin E, Travagli JP** 1998 [Papillary and follicular cancers of the thyroid]. *Presse Med* 27:1479-81.
208. **Ghossein RA, Bhattacharya S, Rosai J** 1999 Molecular detection of micrometastases and circulating tumor cells in solid tumors. *Clin Cancer Res* 5:1950-60.
209. **Bojunga J, Zeuzem S** 2004 Molecular detection of thyroid cancer: an update. *Clin Endocrinol (Oxf)* 61:523-30